PDS Biotechnology

$5.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.43 (-7.90%) Today

$0.00 (0.00%) As of 10:00 PM UTC after-hours

Why Robinhood?

You can buy or sell PDSB and other stocks, options, and ETFs commission-free!

About PDSB

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection.

CEO

Frank K. Bedu-Addo

Employees

Headquarters

Princeton, New Jersey

Founded

2005

Market Cap

99.43M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

623.88K

High Today

$5.50

Low Today

$4.95

Open Price

$5.50

Volume

503.84K

52 Week High

$7.30

52 Week Low

$0.664

PDSB Earnings

-$1.10

-$0.73

-$0.37

$0.00

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Estimated

— per share

Actual

Expected May 12, Pre-Market